Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD)

Abstract

A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic BMT from his one locus-mismatched mother, the diagnosis being confirmed on day +82. Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexa- methasone) followed by two doses of EBV-specific CTL and one dose of unstimulated donor leukocytes were not successful. We assume delay of infusions (day +100, +107) and insufficient CTL cell doses (total 9.2 × 106) may have been responsible for the poor outcome in this case.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imashuku, S., Goto, T., Matsumura, T. et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 20, 337–340 (1997). https://doi.org/10.1038/sj.bmt.1700883

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1700883

Keywords

This article is cited by

Search

Quick links